Press Release

BiondVax Receives Patent Registration Approval for Multimeric Multiepitope Influenza Vaccines in Hong Kong as well as Allowance of Patent Registration in US for the Company's Universal Flu Vaccine

Company considers the Hong Kong and US approvals to be of great importance, as these patents will complement the company's business strategy of universal flu vaccine stockpiling agreements with governments around the world

Nes Ziona, Israel – February 10th, 2014 – BiondVax (TASE: BNDX), developer of a universal flu vaccine, announced receiving approval from Hong Kong's patent office to register its patent concerning Multimeric Multiepitopes for the Company's universal flu vaccine, as well as an approval from the US patent office for the completion of the testing process for patent registration. As part of the US registration process, the patent was found eligible and currently is pending fees. The patent addresses the vaccine structure and composition as well as the manufacturing methods and the usages of the universal flu vaccine, while providing scope for possible changes in the structure of the protein that is the basis for the universal vaccine. The patent extends and secures the coverage provided by existing patents that protect BiondVax's intellectual property.

These approvals in Hong Kong and the US build on patent approvals already received in Australia, China, Russia and Mexico. In parallel, the Company is in the process of registering the patent in other locations worldwide such as Europe and Israel.

BiondVax's business model is to engage in multi-year stockpiling agreements with health organizations and governments around the world, for stockpiling BiondVax's universal vaccine as a pandemic primer vaccine, agreements that would include completion of clinical trials and regulatory approvals in each country, as needed. Since the appearance of new and potentially pandemic flu strains in humans often occurs in Asia, BiondVax has made sure to secure patent approvals in this region, including in Hong Kong.

BiondVax recognizes an interest and a need among various governments around the world to prepare ahead of time for a flu pandemic. The Company estimates that the clinical information gathered and analyzed by the company to date supports that BiondVax's universal flu vaccine can serve as a pandemic primer. More specifically, the data indicates that if BiondVax's universal flu vaccine is given to citizens immediately following a pandemic flu outbreak, and then subsequently the conventional pandemic specific vaccine is administered, the result expected is that more people would be protected against a broader set of flu strains. The Company considers that taking this approach has unique advantages as it enables countries to be prepared right now, ahead of any flu outbreak, so that once the pandemic outbreak is official, the governments could protect their people and keep their country safe –both its health and economy.

"This important patent expands BiondVax's intellectual property, and will help our goal of signing agreements with governmental organizations", said **Ron Babecoff, CEO of BiondVax**. "BiondVax believes it is critical to achieve preparedness for a deadly pandemic flu ahead of outbreak, and that the universal vaccine can already enable governments today to protect their populations for when the pandemic flu breaks out."

About BiondVax Pharmaceuticals Ltd

BiondVax is a publicly traded (TASE: BNDX), advanced clinical stage biotech company dedicated to improving global protection against influenza, with its lead product a universal influenza (flu) vaccine called M-001. Influenza (flu) is the most common infectious disease, caused by countless flu strains as the virus mutates unpredictably and frequently. Current seasonal and pandemic/pre-pandemic flu vaccines rely predominantly on triggering immunity to variable viral regions and accordingly are strain-specific. The vaccines are manufactured based on global surveillance each season or to prepare for a predicted pandemic threat and are often mismatched to the emerging flu strains. Therefore there is an urgent need for broadly protective flu vaccines especially in the case of pandemics and this is being addressed by BiondVax.

At this point in time, BiondVax's universal flu vaccine (M-001) has several unique competitive advantages: the universal flu vaccine at the most advanced stage of clinical development (4 clinical trials with about 440 people); an excellent safety profile; triggers both arms of our immune defenses, cellular and humoral (antibodies); active without the need for an adjuvant; easily, quickly and cheaply manufactured in only 6-8 weeks (conventional flu vaccines take 6-8 months); can be produced year-round and stockpiled as its composition does not change; and finally, M-001 has two indications, as a universal flu vaccine and as an enhancer of conventional strain-specific seasonal/pandemic flu vaccines. Of note, this second indication provides a shorter and cost-effective pathway for clinical development, regulatory approval and commercialization of M-001 and provides a new approach to pandemic preparedness AHEAD of flu outbreak.

For further information, please contact:

Sharon Levin
Gelbert- Kahana
Tel: +972 3 607 4717
Mob: +972-54-4860339
sharonl@gk-biz.com

שרון לוין
גלברט כהנא
טל: +972-3-6074717
נייד: +972-54-4860339

BiondVax`s estimates regarding the future development of the vaccine and expected trials with respect to the vaccine are forward looking information based on the information that BiondVax has in its possession today pertaining to the potential of the vaccine`s development. These estimates may not be realized, in whole or in part, and/or may be realized differently than estimated, as a result of different factors, including the failure to reach the objectives of the trials and/or schedules and/or to obtain the necessary funding for the continuation of development of the vaccine as well as other factors which are not within BiondVax's control and the materialization of any of the risk factors detailed in Section 5.27 of BiondVax`s shelf prospectus published on January 8, 2014.